Clinical trial NCT00800709: Memantine and Changes of Biological Markers and Brain PET Imaging in Alzheimer's Disease
Official title: Changes of Biological Markers and Brain PET Imaging and Clinical Effects of Memantine for Patients With Moderate to Severe Alzheimer's Disease: a 24 Week Double-blind, Randomized, Placebo-Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Alzheimer's Disease
Keywords: Alzheimer's Disease
tau protein
PET
Memantine
Lead sponsor: Shanghai Mental Health Center
Sponsor class: OTHER
Collaborators: name: H. Lundbeck A/S
First posted: 2008-12-02
Enrollment: 26
Sex: ALL
Minimum age (years): 50
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In AD, tau protein is abnormally hyperphosphorylated. Significant changes of hyperphosphorylated tau levels in CSF are found in AD patients. It has been shown in vitro that memantine can reverse abnormal hyperphosphorylation of tau in hippocampal neurons of rats. A statistically significant reduction of CSF phosphorylated tau at a preliminary 1-year follow-up was observed, from median 126 (interquartile range 107-153) to 108 (88-133) ng/l (p = 0.018). No statistically significant differences of total tau or Aβ42 were found (Gunnarsson MD, 2007).

FDG-PET has the unique ability to estimate the local cerebral metabolic rate of glucose consumption, thus providing information on the distribution of neuronal death and synapse dysfunction in AD in vivo (Herholz K. 2003). Synaptic dysfunction and loss induce a reduction in neuronal energy demand that results in decreased glucose metabolism. Hypometabolism in AD is thought to reflect loss of synaptic activity and density (Herholz K. 2003; Mielke R, et al. 1998).

Another biological markers such as inflammatory factor and APOEε4 also play a part in the onset of AD (Glodzik-Sobanska L, 2007).

Detailed description: 1. To investigate the effects of daily dosing of memantine for 24 weeks versus placebo on biological markers of subjects with Alzheimer's disease.
2. To investigate the effects of daily dosing of memantine for 24 weeks versus placebo on 18\[F\]-FDG-PET of brain in subjects with Alzheimer's disease.
3. To investigate the effects of daily dosing of memantine for 24 weeks versus placebo on cognitive function in subjects with Alzheimer's disease.
4. To investigate the effects of daily dosing of memantine for 24 weeks versus placebo on measures of behavior and activities of daily living of subjects with Alzheimer's disease.
5. To investigate the effects of daily dosing of memantine for 24 weeks versus placebo on short term memory.

Eligibility criteria: Inclusion Criteria:

1. Written informed consent
2. Clinical diagnosis of Alzheimer's disease which meet the DSM-IV criteria.
3. Subject has moderate to severe Alzheimer's disease as defined by a MMSE score 4 to 20 inclusive at screening.
4. Hachinski Ischemia Score \< 4 at screening.
5. Age ≥50 and ≤90 years.
6. Availability of a responsible and steady caregiver to ensure treatment compliance and provide information for assessments.

Exclusion Criteria:

1. Severe renal impairment.
2. History of seizures
3. Systolic blood pressure \>160 or \< 90 mmHg or diastolic blood pressure \> 95 or \< 60 mmHg at the time of screening.
4. Diagnosis of any concomitant life threatening illness.

Primary outcomes:
measure: biological markers of CSF
timeFrame: 24 weeks
measure: 18[F]-FDG-PET of brain
timeFrame: 24 weeks
measure: cognitive function
timeFrame: 24 weeks
Secondary outcomes:
measure: behavior and activities of daily living
timeFrame: 24 weeks
measure: short term memory
timeFrame: 24 weeks
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Department of Psychogeriatrics，Shanghai Mental Health Center
state: Shanghai
Study officials:
affiliation: Department of Psychogeriatrics，Shanghai Mental Health Center
name: Shifu Xiao, MD. PhD.
role: PRINCIPAL_INVESTIGATOR
References: